Poseida Therapeutics, Inc. is a medium risk pharmaceutical company based in the United States of America, with an ESG score of 27.4. Specializing in non-viral gene engineering technologies, Poseida Therapeutics is dedicated to developing groundbreaking therapeutics for patients in need. Their pipeline includes innovative CAR-T product candidates for treating various cancers, with a focus on hematological malignancies and solid tumors.